Reuters, June 16, 2011TEL AVIV, June 16 (Reuters) - Israel's BiondVax Pharmaceuticals said on Thursday it had positive results from the first Phase II clinical trial of its universal flu vaccine.
"We have confirmed, in what is to our knowledge the first Phase II study of a universal influenza vaccine ever conducted in the world, that the Multimeric-001 vaccine is not only safe and immunogenic on its own, but it also has the potential to enhance the performance of traditional strain-dependant flu vaccines," Ron Babecoff, BiondVax's CEO, said.
BiondVax is preparing to conduct the next Phase II trial, in the elderly...
Full story
No comments:
Post a Comment